Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin 0.5% for non-perforated bacterial corneal ulcers
ISRCTN10323655Phase 3Completed
- Sponsor
- Dr. Rajendra Prasad Centre for Ophthalmic Sciences
- Start
- Feb 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of moxifloxacin in bacterial keratitis, sponsored by Dr. Rajendra Prasad Centre for Ophthalmic Sciences. Primary endpoints: Time to epithelialisation at 3 months and Time to resolution of the infiltrates at 3 months. Started Feb 2009; status: completed.
02
Drugs
moxifloxacin
03
Conditions
bacterial keratitis
Beyond the preview
Go deeper on ISRCTN10323655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10323655.